Shortcomings Of Best Practices Report On Drug Labeling

Law360, New York (July 23, 2013, 12:34 PM EDT) -- When it was signed into law by President Obama on July 12, 2012, the Food and Drug Administration Safety Information Act, Pub. L. No. 112-144, 126 Stat. 1055 (2012) (FDASIA) was best known for its five-year reauthorization of brand pharmaceuticals user fees and the creation of a new user-fee program for generic and biosimilar products. However, the FDASIA contains a number of additional provisions, some of which relate to improving patient access to medical treatments and technologies.

Among these is Section 904, which authorizes the Architectural...
To view the full article, register now.